Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6588041 | 1.00 | EGFR (0.40) | EGFRERBB2ALDH1A1GAAERBB4 | |
| SCHEMBL24167727 | 1.00 | EGFR (0.40) | EGFRERBB2ALDH1A1GAAERBB4 | |
| SCHEMBL20605289 | 0.85 | ALDH1A1 (0.40) | ALDH1A1GAAMAPTIMPDH2NPC1 | |
| SCHEMBL20605293 | 0.85 | ALDH1A1 (0.40) | ALDH1A1GAAMAPTIMPDH2NPC1 | |
| SCHEMBL19322331 | 0.82 | ALDH1A1 (0.38) | ALDH1A1GAAMAPTIMPDH2NPC1 | |
| SCHEMBL19322333 | 0.80 | ALDH1A1 (0.41) | ALDH1A1GAAMAPTIMPDH2NPC1 | |
| SCHEMBL30478652 | 0.78 | ALDH1A1 (0.35) | ALDH1A1GAAMAPTIMPDH2NPC1 | |
| SCHEMBL2249233 | 0.77 | IMPDH2 (0.36) | ALDH1A1GAAMAPTIMPDH2LMNA | |
| SCHEMBL14536912 | 0.77 | IDO1 (0.52) | ALDH1A1GAAMAPTRAB9A | |
| SCHEMBL2249224 | 0.77 | ALDH1A1 (0.37) | ALDH1A1GAAMAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000039-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | WYETH CORP (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-0980244-B1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | WYETH CORP (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6323209-B1 | QUINAZOLINE COMPOUNDS IN THE TREATMENT AND INHIBITION OF COLONIC POLYPS. | AMERICAN CYANAMID COMPANY | 2001-11-27 | — | — | US | disclosed |
| US-6251912-B1 | Substituted quinazoline derivatives | AMERICAN CYANAMID COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-1039910-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | American Cyanamid Company (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1000039-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | American Cyanamid Company (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0980244-A1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | American Cyanamid Company (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1999024037-A1 | USE OF QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR TREATING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999009016-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1998050038-A1 | USE OF QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0787722-A1 | Substituted quinazoline derivatives | American Cyanamid Company (US) | 1997-08-06 | — | — | EP | disclosed |